Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.

MLA

Zhiyong Peng, et al. “Decitabine-Based Treatment Strategy Improved the Outcome of HSCT in JMML: A Retrospective Cohort Study.” Frontiers in Immunology, Sept. 2024, pp. 01-11. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1426640.

APA

Zhiyong Peng, Jingyu Gao, Litao Huang, Yuelin He, Haoran Tang, Sa Zong, Yanru Pei, Fuyu Pei, Jing Ge, Xuan Liu, Li Yue, Jun Zhou, Xia Li, Dan Yue, Yun Chen, Chen Chen, Xuedong Wu, Xiaoqin Feng, & Chunfu Li. (2024). Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study. Frontiers in Immunology, 01-11. https://doi.org/10.3389/fimmu.2024.1426640

Chicago

Zhiyong Peng, Jingyu Gao, Litao Huang, Yuelin He, Haoran Tang, Sa Zong, Yanru Pei, et al. 2024. “Decitabine-Based Treatment Strategy Improved the Outcome of HSCT in JMML: A Retrospective Cohort Study.” Frontiers in Immunology, September, 01-11. doi:10.3389/fimmu.2024.1426640.